MYCOBACTERIUM-LEPRAE DNA CONTENT, CELLULAR AND CYTOKINE PATTERNS IN SKIN-LESIONS OF LEPROSY PATIENTS UNDERGOING MULTIDRUG THERAPY (MDT)

Citation
Hd. Flad et al., MYCOBACTERIUM-LEPRAE DNA CONTENT, CELLULAR AND CYTOKINE PATTERNS IN SKIN-LESIONS OF LEPROSY PATIENTS UNDERGOING MULTIDRUG THERAPY (MDT), Immunobiology, 191(4-5), 1994, pp. 388-394
Citations number
9
Categorie Soggetti
Immunology
Journal title
ISSN journal
01712985
Volume
191
Issue
4-5
Year of publication
1994
Pages
388 - 394
Database
ISI
SICI code
0171-2985(1994)191:4-5<388:MDCCAC>2.0.ZU;2-K
Abstract
Skin biopsies from untreated and MDT-treated patients were examined fo r infiltrating cells and cells producing the cytokines TNF-alpha, IFN- gamma, and IL-1 beta using immunohistochemistry. Biopsy specimens item untreated tuberculoid leprosy patients were characterized by the pres ence of cells producing TNF-alpha, IFN-gamma, and IL-1 beta and of sub epidermal Langerhans cells. These cells were rarely found or completel y absent in biopsies of untreated lepromatous leprosy patients, but te nded to increase under MDT. In a short-term therapy trial for three mo nths with brodimoprim, dapsone, and rifampicin, 12 patients were monit ored by follow-up biopsies. Semiquantitative PCR for mycobacterial DNA revealed two groups of patients: one group in which mycobacterial DNA in follow-up biopsies remained constant and a second group in which a decrease of mycobacterial DNA during therapy was noted. Immunophenoty ping in these follow-up biopsies revealed that in the latter group IFN -gamma-positive cells and Langerhans cells were present and gamma delt a T cell receptor-positive cells tended to decrease during therapy. In contrast, in patients whose mycobacterial DNA did not change during t herapy, these phenotypical manifestations were nor observed. We theref ore, conclude that assessment of mycobacterial DNA in combination with phenotyping of infiltrating cells and determination of cytokine patte rns may be useful tools in establishing criteria for the effectiveness and duration of MDT in patients with leprosy.